Preclinical tests show mRNA-based treatments effective for blinding condition

A preclinical study by Mass Eye and Ear investigators showed that a novel mRNA-based therapy may be able to prevent blindness and scarring from proliferative vitreoretinopathy (PVR) following a retinal detachment repair or traumatic injury to the eye. There is no current treatment for PVR other than surgery, which itself carries a high risk of causing or exacerbating PVR.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup